NEUROIMAGING IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE: FROM STRUCTURAL MRI TO MOLECULAR IMAGING AND THE BIOLOGICAL AT(N) FRAMEWORK

Authors

  • Madjidova Y. N.¹, Radjapov A. A.1, Shakhabiddinov T. T.¹ ¹ Neurology, child neurology and medical genetics, TSMU, Tashkent, Uzbekistan Author

Keywords:

Alzheimer’s disease; neuroimaging; magnetic resonance imaging; amyloid PET; tau PET; biomarkers; AT(N); diagnostic criteria.

Abstract

Neuroimaging has become an indispensable component of the diagnostic pathway in Alzheimer’s disease (AD), a condition increasingly defined by its underlying biology rather than by clinical syndrome alone. Structural magnetic resonance imaging (MRI) remains the first-line modality: it excludes surgically relevant or potentially reversible causes of cognitive decline, characterises the pattern of medial temporal and posterior cortical atrophy, and quantifies the vascular burden that frequently coexists with AD. Standardised visual rating scales—including the medial temporal atrophy (Scheltens) scale, the Koedam posterior atrophy scale, and the Fazekas scale for white-matter change—improve the reproducibility of these assessments, while automated morphometry and machine-learning tools are expanding the precision and scalability of image analysis. Molecular and functional imaging, chiefly [18F]fluorodeoxyglucose, amyloid, and tau positron emission tomography (PET), enables the pathological hallmarks of AD to be detected in vivo, often years before overt atrophy appears. In parallel, cerebrospinal fluid and, more recently, accurate plasma biomarkers such as phosphorylated tau 217 have transformed access to biological confirmation. These advances underpin a shift from syndromic to biological diagnostic criteria, from the 2011 National Institute on Aging–Alzheimer’s Association recommendations and the International Working Group criteria to the AT(N) system and the 2024 revised criteria. This review synthesises the contemporary evidence on structural, functional, and molecular neuroimaging in AD, integrates it with fluid biomarkers and current diagnostic frameworks, and outlines a practical, imaging-anchored diagnostic approach together with its limitations and future directions.

References

1.Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143–5169. doi:10.1002/alz.13859

2.Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562. doi:10.1016/j.jalz.2018.02.018

3.Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–496. doi:10.1016/S1474-4422(21)00066-1

4.Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67–77. doi:10.1038/nrneurol.2009.215

5.Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–972. doi:10.1136/jnnp.55.10.967

6.Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, et al. Visual assessment of posterior atrophy: development of a MRI rating scale. Eur Radiol. 2011;21(12):2618–2625. doi:10.1007/s00330-011-2205-4

7.Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356. doi:10.2214/ajr.149.2.351

8.Haller S, Vernooij MW, Kuijer JPA, Larsson E-M, Jäger HR, Barkhof F. Cerebral microbleeds: imaging and clinical significance. Radiology. 2018;287(1):11–28. doi:10.1148/radiol.2018170803

9.Zhao Z, Chuah JH, Lai KW, Chow C-O, Gochoo M, Dhanalakshmi S, et al. Conventional machine learning and deep learning in Alzheimer’s disease diagnosis using neuroimaging: a review. Front Comput Neurosci. 2023;17:1038636. doi:10.3389/fncom.2023.1038636

10.Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319. doi:10.1002/ana.20009

11.Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):e1–e16. doi:10.1016/j.jalz.2013.01.002

12.Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–1294. doi:10.1001/jama.2019.2000

13.Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097–2109. doi:10.1007/s00259-020-05118-w

14.Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772–781. doi:10.1001/jama.2020.12134

15.Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255–263. doi:10.1001/jamaneurol.2023.5319

16.McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058

17.Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367–385. doi:10.1016/j.jalz.2011.05.2351

18.van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. doi:10.1056/NEJMoa2212948

19.Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–527. doi:10.1001/jama.2023.13239

20.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269. doi:10.1016/j.jalz.2011.03.005

21.Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–262. doi:10.1016/j.jalz.2011.03.004

Downloads

Published

2026-07-20